Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million , up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01
– Call Scheduled for Tuesday, November 14, 2023 , at 9:00 a.m. ET – DENVER --(BUSINESS WIRE)--Nov. 7, 2023-- TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and
– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial – – Median
– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors – DENVER & SAN DIEGO --(BUSINESS WIRE)--Nov. 3, 2023-- TriSalus Life Sciences® Inc.
DENVER --(BUSINESS WIRE)--Oct. 25, 2023-- TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will present a variety of new data from
Devlin Brings Significant Expertise in Commercialization, Sales and Marketing DENVER --(BUSINESS WIRE)--Sep. 6, 2023-- TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with
Advances TriSalus’ Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in
New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels DENVER and CHICAGO, June 12, 2023 – TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of
DENVER and FORT LAUDERDALE, Fla., April 20, 2023 – TriSalus Life Sciences® Inc., (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC)
*** MEDIA ADVISORY *** PHOENIX, February 28, 2023 – TriSalus Life Sciences® Inc., (“TriSalus” or the “company”), an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors, will participate